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Abstract
Background: Oxidative stress and impaired antioxidant system have been proposed as a potential
factors involved in the pathophysiology of diverse disease states, including carcinogenesis. In this
study, we explored the lipid peroxidation levels and antioxidant enzyme activities in women
diagnosed with different forms of gynecological diseases in order to evaluate the antioxidant status
in endometrium of such patients.
Methods: Endometrial tissues of gynecological patients with different diagnoses were collected
and subjected to assays for superoxide dismutase, catalase, glutathione peroxidase, glutathione
reductase and lipid hydroperoxides.
Results: Superoxide dismutase activity was significantly decreased (50% in average) in hyperplastic
and adenocarcinoma patients. Activities of both glutathione peroxidase and glutathione reductase
were increased 60% and 100% on average, in hyperplastic patients, while in adenocarcinoma
patients only glutathione reductase activity was elevated 100%. Catalase activity was significantly
decreased in adenocarcinoma patients (47%). Lipid hydroperoxides level was negatively correlated
to superoxide dismutase and catalase activities, and positively correlated to glutathione peroxidase
and glutathione reductase activities.
Conclusions: This study provided the first comparison of antioxidant status and lipid peroxidation
in endometrial tissues of patients with polyps, myoma, hyperplasia and adenocarcinoma. The results
showed that patients with premalignant (hyperplastic) and malignant (adenocarcinoma) lesions had
enhanced lipid peroxidation and altered uterine antioxidant enzyme activities than patients with
benign uterine diseases, polyps and myoma, although the extent of disturbance varied with the
diagnosis. Further investigation is needed to clarify the mechanisms responsible for the observed
alterations and whether lipid hydroperoxide levels and antioxidant enzyme activities in uterus of
gynecological patients might be used as additional parameter in clinical evaluation of gynecological
disorders.
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It is now well known that free radicals and other reactive
oxygen species (ROS) are continuously produced in all
cells as a part of normal metabolism and in a wide variety
of disease processes [1]. Deleterious effects of ROS and
lipid peroxidation (LPO) products are counteracted by
antioxidant (AO) defense system, which consists of
nonenzymatic antioxidant molecules and antioxidant
enzymes (AOE) such as superoxide dismutase (SOD), cat-
alase (CAT), glutathione peroxidase (GPx), glutathione
reductase (GR) and glutathione transferase (GST), [2].
Studies on the implication of oxidative stress in gyneco-
logic disorders have not received adequate attention, and
data regarding mechanisms underlying these diseases are
sporadic. Findings suggest that maintenance of pro-anti-
oxidant equilibrium is important in physiology of repro-
duction [3], embryopathies and pregnancy [4]. Clinical
investigations indicate that women with certain common
benign gynecological diseases, such as endometriosis and
uterine leiomyoma, may have increased risk of develop-
ing malignant tumors [5]. Two of the most common
malignancies of the female genital tract worldwide are cer-
vical and endometrial cancer [6].
Classic clinicopathologic findings suggest that endome-
trial carcinoma arises through a series of precursor lesions
known as endometrial hyperplasia [7]. According to the
current World Health Organization (WHO) nomencla-
ture, four categories of endometrial hyperplasia exist, sim-
ple (SH), complex (CH), simple atypical (SAH), and
complex atypical (CAH). A new concept of classification
(EIN nomenclature) has been proposed by Mutter et al.
[8], based on integrated morphological, genetic, molecu-
lar, cell biological, and morphometrical studies, accord-
ing to which three disease categories are discerned, benign
hyperplasia, endometrial intraepithelial neoplasia (EIN)
and cancer [9].
Although endometrial hyperplasia is regarded as a prelim-
inary stage of endometrioid carcinoma [10], there is a lack
of data on the relationship between oxidative stress and
antioxidant enzymes in such patients. Some investiga-
tions so far have revealed elevated levels of lipid peroxida-
tion and disturbed AOE activities in endometrial tissue of
patients with benign and malign diseases. In patients with
endometriosis and adenomyosis, SOD and CAT were
found to be abnormally expressed [11,12], while patients
with endometriosis have lowered GPx activity [13]. In
endometrial cancer tissue of both Finnish and Japanese
women, the activity of SOD was significantly lower than
in normal endometrium, while GPx activity and LPO level
were elevated [14]. Our recent results also show that gyne-
cological patients have altered AO status in blood, which
varies with the enzyme and diagnosis. However, both
reduction in antioxidants and elevation of lipid peroxida-
tion were observed in general [15].
Since study on this subject and in this area is still rare, we
aimed to explore the level of lipid peroxidation and AOE
activities in endometrium of patients diagnosed with
myoma, polyps, hyperplasia simplex, hyperplasia com-
plex and adenocarcinoma in order to evaluate the extent
of oxidative stress in endometrial tissue of such patients.
Methods
Subjects
The material used in this study consisted of 88 tissue spec-
imens of women admitted to the Department of Gynecol-
ogy and Obstetrics for gynecological evaluation within
routine checkups or for abnormal uterine bleeding. The
specimens were taken after obtaining the informed con-
sent and the study was conducted prospectively. The pro-
tocol was consistent with the World Medical Association
Declaration of Helsinki (Ethical Principles for Medical
Research Involving Human Subjects).
On the basis of diagnosis and histological examination,
subjects were divided into following groups: patients with
benign uterine changes (representing the control group of
patients with an assumed unaffected endometrium):
polypus endometrii (PE, n = 18, 45 ± 3 yr) or uterine myo-
matosis (UM, n = 12, 47 ± 2 yr); patients with abnormal
bleeding: hyperplasia simplex endometrii (SH, n = 31, 48
± 1 yr), hyperplasia complex endometrii (CH, n = 22, 48
± 2 yr) or adenocarcinoma endometrii, stage I (ACE, n =
5, 59 ± 3 yr).
Samples
After curettage performed under general anesthesia,
endometrial tissue samples were washed immediately in
saline solution and transferred to the laboratory. Upon
receipt of samples they were homogenized in phosphate
buffer containing 0.05 M KH2PO4 and 1 mM EDTA, pH
7.8 (1 g tissue per 2 ml buffer) in a Teflon/glass homoge-
nizer (Spindler & Hoyer, Göttingen, Germany) aliquoted
and frozen at -70°C for 20 h in order to disrupt cell mem-
branes. For SOD assay (OxisResearch™), thawed homoge-
nates were vortexed 1 min and centrifuged at 8600 g, for
20 min at 4°C (Eppendorf centrifuge 5417, Eppendorf
AG, Hamburg, Germany). According to manufacturer's
recommendation, after addition of ethanol/chloroform
extraction reagent (62.5/37.5 vol/vol) to completely
remove hemoglobin interference, samples were centri-
fuged at 6000 g for 20 min, at 4°C (Beckman centrifuge
J2-21, Beckman Instruments Inc., Palo Alto, CA, USA).
Upper aqueous layer was collected and kept at -70°C until
assay. The enzyme activities and lipid hydroperoxide
(LOOH) concentration were monitored spectrophoto-
metrically (Perkin Elmer Spectrophotometer, Lambda 25,Page 2 of 9
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were kept frozen and measurements were performed
within 1 month upon their receipt. The specific enzyme
activities were expressed as Units (U) or mU per milligram
of total cell protein (U or mU/mg protein). LOOH con-
centration was expressed as nmol/mg protein. Determina-
tion of protein concentration was performed in tissues
homogenates by the method of Lowry et al. [16] and
expressed as mg/ml.
Assays
Assay of SOD activity
Determination of SOD activity was performed using Oxis
Bioxytech® SOD-525™ Assay (Oxis International, Inc.,
Portland, OR, USA). The method is based on SOD-medi-
ated increase of autoxidation of 5,6,6a11b-tetrahydro-
3,9,10-tryhydroxybenzo [c]fluorene in aqueous alkaline
solution to yield a chromophore with maximum absorb-
ance at 525 nm. The SOD activity is determined from the
ratio of the autoxidation rates in the presence (Vs) and in
the absence (Vc) of SOD. One SOD-525 activity unit is
defined as the activity that doubles the autoxidation rate
of the control blank.
Assay of CAT activity
CAT activity was determined by the method of Beutler
[17]. The reaction is based on the rate of H2O2 degrada-
tion by catalase contained in the examined samples. The
reaction was performed in an incubation mixture contain-
ing 1 M Tris-HCl, 5 mM EDTA, pH 8.0, and monitored
spectrophotometrically at 230 nm. One unit of CAT activ-
ity is defined as 1 μmol of H2O2 decomposed per minute
under the assay conditions.
Assay of GPX activity
GPx activity was assessed using the Oxis Bioxytech® GPx-
340™ Assay (Oxis International, Inc., Portland, OR, USA),
based on the principle that oxidized glutathione (GSSG)
produced upon reduction of an organic peroxide by GPx,
is immediately recycled to its reduced form (GSH) with
concomitant oxidation of NADPH to NADP+. The oxida-
tion of NADPH was monitored spectrophotometrically as
a decrease in absorbance at 340 nm. One GPx-340 unit is
defined as 1 μmol of NADH oxidized per minute under
the assay conditions.
Assay of GR activity
Activity of GR was measured using the Oxis Bioxytech®
GR-340™ Assay (Oxis International, Inc., Portland, OR,
USA). Assay is based on the oxidation of NADPH to
NADP+ during the reduction of oxidized glutathione
(GSSG), catalyzed by a limiting concentration of glutath-
ione reductase. The oxidation of NADPH was monitored
spectrophotometrically as a decrease in absorbance at 340
nm. One GR-340 unit is defined as 1 μmol of NADH oxi-
dized per minute under the assay conditions.
Lipid hydroperoxides
Concentration of LOOH was measured by Oxis Biox-
ytech® LPO-560™ Assay (Oxis International, Inc., Port-
land, OR, USA), which is based on the oxidation of
ferrous (Fe2+) ions to ferric (Fe3+) ions by hydroperoxides
under acidic conditions. Ferric ions then bind with the
indicator dye, xylenol orange, and form a colored com-
plex. The absorbance of the complex was measured at 560
nm. Since hydrogen peroxide content in many biological
samples is much higher than that of other hydroperox-
ides, samples were pretreated with catalase to decompose
the existing H2O2 and eliminate the interference.
Statistical analysis
Statistical analysis was carried out by use of the nonpara-
metric Kruskal-Wallis test and the Dunn's post hoc test,
which considered the unequal and small sample sizes we
used in this study (values which are not sharing the same
letter are significantly different, p < 0.05). Relative values
for LOOH level and enzyme activities were expressed as
percent of corresponding values in patients with polyps,
which are considered to be 100%. Spearman's rank corre-
lation coefficient was used to investigate associations
between lipid peroxidation and antioxidant enzyme activ-
ities. Two-tailed p values are given throughout. All data
were analyzed using GraphPad Prism 4 software.
Results
Comparing data for the level of lipid hydroperoxides and
antioxidant enzyme activities among five diagnosis
groups, all parameters showed significant variations of the
obtained values (LOOH: H = 37.11, df = 4, p < 0.001;
SOD: H = 31.72, df = 4, p < 0.001; CAT: H = 11.27, df = 4,
p < 0.05; GPx: H = 26.54, df = 4, p < 0.001; GR: H = 29.22,
df = 4, p < 0.001; Kruskal-Wallis).
Figure 1 indicates the lipid peroxidation levels in the
examined groups of patients. Patients with myoma had
comparable LOOH level to that observed in patients with
polyps, whereas it was significantly higher in patients with
simple or complex hyperplasia (50%, p < 0.05) and aden-
ocarcinoma (105%, p < 0.05), compared to polyps and
myoma subjects.
Superoxide dismutase activity is shown in Figure 2. The
SOD activity was not different between polyps and
myoma patients (p > 0.05). Compared to subjects with
benign endometrial changes (polyps and myoma), SOD
activity was significantly decreased in patients with hyper-
plasia simplex (41%, p < 0.05), hyperplasia complex
(53%, p < 0.05) and adenocarcinoma (72%, p < 0.05)
patients.Page 3 of 9
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altered between polyps and myoma patients. Compared
to polyps and myoma subjects, patients with simple and
complex hyperplasia did not have significantly lower CAT
activity (p > 0.05), while in adenocarcinoma patients the
activity was lower by 43% (p < 0.05).
Figure 4 shows glutathione peroxidase activity. Activity of
this enzyme was not different between polyps and myoma
patients (p > 0.05). Patients with hyperplasia simplex had
45% (p < 0.05) higher GPx activity than patients with pol-
yps. Women with complex hyperplasia had 61% (p <
0.05) higher GPx activity than women with polyps or
myoma. There was no difference in GPx activity in adeno-
carcinoma patients in comparison to polyps or myoma
patients (p > 0.05).
Glutathione reductase activity is shown in figure 5. Com-
pared to patients with polyps and myoma, significant ele-
vation of GR activity was recorded in all examined groups,
hyperplasia simplex (108%, p < 0.05), hyperplasia com-
plex (94%, p < 0.05) and adenocarcinoma (120%, p <
0.05).
Correlation analysis (Figure 6) showed that lipid
hydroperoxides level was negatively correlated to SOD (r
= -0.21, p < 0.05) and CAT activity (r = -0.25, p < 0.05),
and positively correlated to GPx activity (r = 0.32, p <
0.01) and GR activity (r = 0.37, p < 0.001) (Figure 6).
Although the correlation coefficient values were low
(indicative of a weak correlation), the correlation was sup-
ported by the p-values showing statistical significance.
Discussion
Oxidative stress and impaired AO system have been pro-
posed as a potential factors involved in the pathophysiol-
ogy of diverse disease states, including carcinogenesis.
This study indicates that women with gynecological disor-
ders have altered activity of antioxidant enzymes and it
also points to elevated levels of lipid peroxidation prod-
ucts, as markers of oxidative stress, in endometrial tissue
of such patients. Namely, higher levels of LOOH were
recorded in patients with endometrial hyperplasia or ade-
nocarcinoma than in patients with benign (polyps) or
presumably unaffected (myoma) endometrial tissue.
Patients with adenocarcinoma had higher LOOH level
than the hyperplastic ones, while there was no difference
in LOOH level between women with benign diagnoses.
Our findings are consistent with previous studies suggest-
ing that elevation of LOOH level might reflect the
impaired oxidant/antioxidant balance in favor of oxidants
and oxidative stress [14,18]. It could also be associated
with degenerative changes in morphological and physio-
A) LOOH concentration (nmol/mg protein) in endometrium of patients diagnosed with: polypus endometrii (PE), uterine myo-matosis (UM), simple hyperplasia (SH), complex hyperplasia (CH) and adenocarcinoma endometrii (ACE)Figure 1
A) LOOH concentration (nmol/mg protein) in endometrium of patients diagnosed with: polypus endometrii 
(PE), uterine myomatosis (UM), simple hyperplasia (SH), complex hyperplasia (CH) and adenocarcinoma 
endometrii (ACE). Mean LOOH concentrations (± SD) are represented by the box; medians are plotted inside a box; the 
whiskers extend to the 5th and 95th percentiles. Values which are not sharing the same letter (a, b) are significantly different (p 
< 0.05). B) Relative values of LOOH concentration in the examined diagnosis, where PE was taken as 100%.
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A) SOD activity (U/mg protein) in endometrium of patients diagnosed with: polypus endometrii (PE), uterine myomatosis (UM), simple h perplasia (SH), complex hyperplasia (CH) an  denocarc noma endometrii (ACE)Figure 2
A) SOD activity (U/mg protein) in endometrium of patients diagnosed with: polypus endometrii (PE), uterine 
myomatosis (UM), simple hyperplasia (SH), complex hyperplasia (CH) and adenocarcinoma endometrii 
(ACE). Mean SOD activities (± SD) are represented by the box; medians are plotted inside a box; the whiskers extend to the 
5th and 95th percentiles. Values which are not sharing the same letter (a, b) are significantly different (p < 0.05). B) Relative val-
ues of SOD activity in the examined diagnosis, where PE was taken as 100%.
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A) CAT activity (U/mg protein) in endometrium of patients diagnosed with: polypus endometrii (PE), uterine myomatosis (UM), simple h perplasia (SH), complex hyperplasia (CH) an  denocarc noma endometrii (ACE)Figure 3
A) CAT activity (U/mg protein) in endometrium of patients diagnosed with: polypus endometrii (PE), uterine 
myomatosis (UM), simple hyperplasia (SH), complex hyperplasia (CH) and adenocarcinoma endometrii 
(ACE). Mean CAT activities (± SD) are represented by the box; medians are plotted inside a box; the whiskers extend to the 
5th and 95th percentiles. Values which are not sharing the same letter (a, b) are significantly different (p < 0.05). B) Relative val-
ues of CAT activity in the examined diagnosis, where PE was taken as 100%.
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A) GPx activity (mU/mg protein) in endometrium of patients diagnosed with: polypus endometrii (PE), uterine myomatosis (UM), simple hyperplasia (SH), complex hype plasia (CH) and ade carcinoma endom trii (ACE)Figure 4
A) GPx activity (mU/mg protein) in endometrium of patients diagnosed with: polypus endometrii (PE), uter-
ine myomatosis (UM), simple hyperplasia (SH), complex hyperplasia (CH) and adenocarcinoma endometrii 
(ACE). Mean GPx activities (± SD) are represented by the box; medians are plotted inside a box; the whiskers extend to the 
5th and 95th percentiles. Values which are not sharing the same letter (a, b, c) are significantly different (p < 0.05). B) Relative 
values of GPx activity in the examined diagnosis, where PE was taken as 100%.
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A) GR activity (mU/mg protein) in endometrium of patients diagnosed with: polypus endometrii (PE), uterine myomatosis (UM), simple hyperplasia (SH), complex hyperplasia (CH) an  denocarcinoma endometrii (ACE)Figure 5
A) GR activity (mU/mg protein) in endometrium of patients diagnosed with: polypus endometrii (PE), uterine 
myomatosis (UM), simple hyperplasia (SH), complex hyperplasia (CH) and adenocarcinoma endometrii 
(ACE). Mean GR activities (± SD) are represented by the box; medians are plotted inside a box; the whiskers extend to the 
5th and 95th percentiles. Values which are not sharing the same letter (a, b) are significantly different (p < 0.05). B) Relative val-
ues of GR activity in the examined diagnosis, where PE was taken as 100%.
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most normal tissues with high cellular turnover (like
endometrium) utilize circulating lipids preferentially for
the synthesis of new structural lipids [19-21], while hyper-
plastic and neoplastic tissues seem to necessitate the addi-
tional sources for more energetic storage, like increased
synthesis of endogenous fatty acids [22,23]. The fatty acid
pathway might promote localized oxidative stress in
hyperplastic tissue and highly proliferative lesions [24].
Superoxide dismutase activity was found to be decreased
in endometrium of patients with hyperplasia and adeno-
carcinoma in comparison to women with polyps or
myoma. In patients with adenocarcinoma, the decrease in
SOD activity was more pronounced than in hyperplastic
subjects. Similar results were obtained in endometrial
cancer tissue of both Finnish and Japanese women [14].
The decrease in enzyme activity appeared to be related to
the decreased levels of SOD protein in the examined tis-
sues [25]. Also, it may be due to an increased endogenous
production of ROS as evidenced by increased lipid
hydroperoxides. In vitro studies indicate that all SOD
enzymes are exquisitely susceptible to oxidative modifica-
tion and inactivation through targeting of tyrosine or his-
tidine residues [26,27]. The SOD activity observed in
patients with polyps and myoma may also point to a role
of oxidative stress in genesis of precancerous lesions and
cancer. Namely, studies suggest that women with certain
common benign gynecological diseases, such as endome-
triosis, leiomyomas or polyps may experience increased
risks of developing malignant tumors [5,28,29]. Research
also suggests that transformed tissues produce high levels
of ROS and are constantly under oxidative stress [30]. The
increase in ROS, such as O2 .-, is able to stimulate cell cycle
progression and promote cell proliferation.
Scatter plot of SOD (A), CAT (B), GPx (C), and GR (D) activities against LOOH levelFigure 6
Scatter plot of SOD (A), CAT (B), GPx (C), and GR (D) activities against LOOH level.
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noma patients when compared to women with polyps or
myoma. Data regarding CAT in uterine pathology are dif-
ferent. Punnonen et al. [14] found that Japanese women
with endometrial cancer did not have significantly altered
CAT activity. Study of Ota et al. [12] showed that women
with endometriosis and adenomyosis had elevated
expression of CAT in comparison to healthy women but
the expression did not show the usual, fluctuating pattern
characteristic for the menstrual cycle. Lower CAT activity,
observed in our study, might enhance the oxidative stress
in patients by lower detoxification of H2O2. Such condi-
tions may accelerate the cell transformation and, by that,
the tumor growth. It is already known that if the O2 .- is not
removed immediately, it may cause the inhibition of CAT
activity [31]. Thus, the lower CAT activity we recorded
might be a consequence of the decreased SOD activity in
hyperplastic and cancer patients. In addition, we found
negative correlation between LOOH level and CAT activ-
ity in the examined patients. It is possible that such rela-
tions contribute to a certain antiapoptotic milieu that is
suitable for enhancing the mutations frequency, a condi-
tion which may lead to the cell transformation and cancer.
Investigations already point to that mechanism [32].
In comparison with polyps or myoma subjects, GPx activ-
ity was increased in patients with hyperplasia. This eleva-
tion was followed by the increase in the GR activity. A
positive correlation between LOOH level and GPx and GR
activities in endometrium was also recorded. Much
research so far has been focused on deleterious effects of
elevated oxygen and nitrogen species as an integral part of
the pathophysiology of many diseases. However, the pre-
cise role of hydroperoxides, as well as of GPx, in gyneco-
logical pathology remains to be determined. Recent
studies indicate that peroxidative stress is one basis for the
pathogenesis of inflammation-associated cancers [33,34].
One of such predisposing conditions closely related to
inflammation and the development of ovarian cancer is
endometriosis [35,36]. Punnonen et al. [14] detected
higher GPx activity in cancer than in normal
endometrium of the Finnish population while in Japanese
women no change of GPx activity was recorded. Ohwada
et al. [37] also observed higher GPx activity in endome-
trial cancer tissue than that from the healthy controls.
Moreover, they found significantly higher GPx activity in
histological grade 1 endometrial cancer than in endome-
trial cancer of histological grades 2 or 3. GPx activity was
also significantly higher in endometrial cancer with mixed
atypical adenomatous endometrial hyperplasia than in
endometrial cancer without endometrial hyperplasia
[37]. In population of Spanish women with epithelial
ovarian carcinoma, Sanchez et al. [38] also observed a sig-
nificantly increased GPx activity compared with control
normal tissue.
Evidence suggests a protective role of overexpressed [39]
or activated [40,41] GPx activity by various environmen-
tal stresses including cancer. However, elevated GPx gene
expression has also been associated with tumorogenesis,
presumably because of its antiapoptotic activity [42-44].
Previous analysis of the histological and clinical features
of endometrial cancer showed that high levels of GPx
activity were associated with well-differentiated adenocar-
cinoma, slight myometrial invasion, and the presence of
concurrent endometrial hyperplasia. These observations
suggested that women with endometrial cancer who had
a high level of GPx activity in their endometrial tissue
were more likely to have a good prognosis; that is, GPx
activity may be a significant prognostic factor for endome-
trial cancer [37].
Conclusions
In summary, this study showed that patients with prema-
lignant (hyperplastic) and malignant (ACE) lesions had
enhanced lipid peroxidation and altered uterine antioxi-
dant enzyme activities than patients with benign uterine
diseases, polyps and myoma, although the extent of dis-
turbance varied with the diagnosis. Generally, it is not
unknown that AO defense system is altered in response to
various diseases and that oxidative stress may be a com-
mon pathogenic mechanism implicated in the pathogen-
esis of diverse disease states, including gynecological
disorders. Although our results do not allow us to draw a
conclusion whether the recorded changes in AOE activi-
ties in hyperplastic and carcinoma patients are the cause
or the consequence of increased oxidative stress, they pro-
vided the first comparison of AO status and lipid peroxi-
dation in patients with uterine polyps, myoma,
hyperplasia and adenocarcinoma. Further investigation
should determine whether lipid hydroperoxide levels and
AOE activities in uterus of gynecological patients might be
used as additional parameters in clinical evaluation of the
stage of gynecological disorders.
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